Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 2/2008

01-02-2008 | Correspondence

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

Authors: Kalman Kovacs, Bernd W. Scheithauer, Matilde Lombardero, Roger E. McLendon, Luis V. Syro, Humberto Uribe, Leon D. Ortiz, Luis C. Penagos

Published in: Acta Neuropathologica | Issue 2/2008

Login to get access

Excerpt

Temozolomide, an alkylating imidazol tetrazine derivative, inhibits DNA replication and is used successfully in the management of patients with gliomas and other malignancies [5, 12]. Recent studies showed the drug to be effective in patients with pituitary carcinoma and aggressive pituitary adenoma [1, 2, 7, 10, 14]. …
Literature
1.
Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Pepin SE, Simmons NE (2004) Pituitary carcinomas respond to temozolomide. Neurooncol 6:374
2.
Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105:621–626PubMed
3.
Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMed
4.
Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38:185–189PubMedCrossRef
5.
Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406PubMedCrossRef
6.
Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T (2006) Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106:1759–1765PubMedCrossRef
7.
Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7:518–520PubMedCrossRef
8.
McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS (1998) Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 78:643–644PubMed
9.
Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385PubMedCrossRef
10.
Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10:81–86PubMedCrossRef
11.
Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24:3431–3437PubMedCrossRef
12.
Stupp R, Gander M, Leyvraz S, Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2:552–560PubMedCrossRef
13.
Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65:552–553CrossRef
14.
Zhu Y, Shaninian H, Hakimian B, Bonert V, Lim S, Heaney A (2004) Temodar: novel treatment for pituitary carcinoma (Abstract). US Endocr Soc 138:43–45
Metadata
Title
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
Authors
Kalman Kovacs
Bernd W. Scheithauer
Matilde Lombardero
Roger E. McLendon
Luis V. Syro
Humberto Uribe
Leon D. Ortiz
Luis C. Penagos
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 2/2008
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-007-0279-5

Other articles of this Issue 2/2008

Acta Neuropathologica 2/2008 Go to the issue

Original Paper

Spinal cord tau pathology in cervical spondylotic myelopathy

Original Paper

Tracing of temporo-entorhinal connections in the human brain: cognitively impaired argyrophilic grain disease cases show dendritic alterations but no axonal disconnection of temporo-entorhinal association neurons

Case Report

Neurodegeneration involving putative respiratory neurons in Perry syndrome

Announcements

Kurt Jellinger Prize 2008 for outstanding scientific writing in neuropathology

Original Paper

Heat shock protein 70 expression in epilepsy suggests stress rather than protection

Original Paper

Shifting of parvalbumin expression in the rat retina in experimentally induced diabetes